TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05375877

Intervention type: DEVICE
Group type: OTHER
Intervention: iATROS
Description: The digital eHealth platform of iATROS in combination with a wearable will be used independently by the subjects of the study. In particular, the reminder function is used to remind patients to record their ECGs, take medication and perform other tasks they may have created themselves, or to use other iATROS functions, such as teleconsultation or remote medical data reporting. Furthermore, the designed training program for atrial fibrillation patients teaches them how to deal with their own disease.~If unhealthy or dangerous vital signs are detected during the use of these medical devices over a longer period of time, the patient receives feedback through the application for medical presentation. This includes the detection of atrial fibrillation recurrences.
Study: NCT05316142

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AGV implantation
Description: This method will use Ahmad FP7 model valved shunt (New World Medical, LA), which is one of the most commonly used shunts in the world

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AGV implantation
Description: This method will use Ahmad FP7 model valved shunt (New World Medical, LA), which is one of the most commonly used shunts in the world
Study: NCT05273918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitivo-comportmental therapy
Description: 15 workshops once a week during 90 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: body mediation
Description: 15 workshops once a week during 90 minutes
Study: NCT04576663

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline infusion simultaneous with subarachnoid block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Different infusion dose of phenylephrine simultaneous with subarachnoid block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Different infusion dose of phenylephrine simultaneous with subarachnoid block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Different infusion dose of phenylephrine simultaneous with subarachnoid block
Study: NCT06393946

Intervention type: DRUG
Intervention: Dupilumab
Description: This study will not administer any treatment, only observe the treatment as prescribed in real world-clinical practice.
Study: NCT06135142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connective Tissue Massage
Description: It involves manipulating the soft and deep tissues of the body.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: The sum of therapeutic modalities of physical medicine capable to change the threshold of elicitation of nerve or muscle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical Massage
Description: It involves manipulating the soft tissues of the body.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapatic Ultrasound
Description: The sum of therapeutic modalities of physical medicine capable to change the threshold of elicitation of nerve or muscle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heat Treatment
Description: Applying heat to an affected area to treat damaged muscles, joints or tissues in the body.
Study: NCT06277609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF28996
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF28996
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefenamic Acid
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid
Description: Tablet
Study: NCT05076552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACH101
Description: Orally via capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACH101
Description: Orally via capsules
Study: NCT05686876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of PsA by PET/CT.
Study: NCT04964375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABSK043 oral capsule
Description: ABSK043 is a novel, oral small molecule inhibitor of PD-L1
Study: NCT02837601

Intervention type: DEVICE
Group type: OTHER
Intervention: AirSeal® Insufflation System (AIS)
Description: The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® iFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal. Specifically, the AirSeal® System creates a pressure barrier within the proximal housing of the cannula which acts as an invisible seal to maintain pneumoperitoneum during the course of surgery. It utilizes a re-circulation and filtration control unit (AirSeal® iFS) designed specifically for the AirSeal® Access Port to create and maintain the pressure barrier.

Intervention type: DEVICE
Group type: OTHER
Intervention: AirSeal® Insufflation System (AIS)
Description: The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® iFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal. Specifically, the AirSeal® System creates a pressure barrier within the proximal housing of the cannula which acts as an invisible seal to maintain pneumoperitoneum during the course of surgery. It utilizes a re-circulation and filtration control unit (AirSeal® iFS) designed specifically for the AirSeal® Access Port to create and maintain the pressure barrier.
Study: NCT04056910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivosidenib and nivolumab
Description: Ivosidenib will be administered orally at a dose of 500 mg (provided as 250 mg strength tablets) daily. The dose may be reduced to 250 mg for patients experiencing more than one event of Grade 2 nausea or vomiting (related or unrelated), or Grade 3 or Grade 4 adverse events.~Nivolumab will be administered at 480 mg IV every 28 days.
Study: NCT05536986

Intervention type: OTHER
Intervention: Stressors
Description: Patients are exposed to stressful situations related to the diagnosis and treatment of the disease
Study: NCT05471791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Back2Play App
Description: This App uses the Apple watch to monitor activity level and heart rate and combines this with self reported symptoms and stage of recovery to send notifications, suggestions and provide resources to help participants adhere to the guidelines.
Study: NCT05499312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HKIIM-KU formula
Description: Subjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo granules (16.9g twice daily) for 8 weeks.
Study: NCT05863832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprodiazole
Description: Ciprofolxacin 500 mg / Metronidazole 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin Tablets & Metronidazole tablets
Description: Ciprofolxacin 500 mg + Metronidazole 500 mg
Study: NCT05601284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy
Description: ACT teaches skills to develop acceptance, mindfulness, and defusion from difficult internal experiences while increasing connections with personal values and encouraging meaningful behavioral changes. ACT for misophonia combines core ACT processes with a traditional audiological behavioral intervention for a integrated, multi-disciplinary approach for the assessment and treatment of misophonia. Treatment begins with a brief focus on the behavioral intervention, followed by the teaching of ACT skills to support the use of the behavioral methods. The intervention consists of 12 total individual sessions of ACT+behavioral management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive relaxation training
Description: PRT for misophonia consists of basic psychoeducation for misophonia followed by PRT. PRT involves learning to tense and relax muscles. Early sessions focus on tensing and relaxing smaller muscle groups, while later sessions focus on larger muscle groups. Final sessions focus on relaxation as produced by recalling previous relaxation and a review of skills learned. PRT consists of 12 individual total sessions.
Study: NCT05501730

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantra QPlus System
Description: Coagulation monitoring system
Study: NCT06361485

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lumbar Injections with 10cc's of Wharton's Jelly Allograft
Description: Low Back Injections with Minimal Manipulation Umbilical Cord Tissue
Study: NCT05916014

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Test: The diagnosis of Artificial Intelligence and endosopists
Description: Endosopists and AI will assess the Kimura-Takemoto classification independently when the patients is eligible.
Study: NCT05623098

Intervention type: DIETARY_SUPPLEMENT
Intervention: dietary fiber nutrients
Description: Whether to add nutrients containing dietary fiber
Study: NCT06076616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation and rehabilitation
Description: A personalized lifestyle counseling programme.
Study: NCT05538702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQOS 3.0 DOU with bland taste unit (Heated Tobacco Product)
Description: Heated tobacco products (HTP) are devices which heat but do not burn tobacco. They do not produce cigarette smoke but rather an aerosol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQOS 3.0 DUO with menthol taste unit (Heated Tobacco Product)
Description: Heated tobacco products (HTP) are devices which heat but do not burn tobacco. They do not produce cigarette smoke but rather an aerosol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Marlboro Gold (Conventional cigarette)
Description: Conventional cigarette

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: IQOS 3.0 DUO turned off with a bland taste unit
Description: Placebo device
Study: NCT05753423

Intervention type: DIAGNOSTIC_TEST
Intervention: Interview-based questionnaires & Clinical examination
Description: Interview-based questionnaires will be conducted among Egyptian mothers attending Pediatric Dentistry and Dental Public Health outpatient clinic at Faculty of Dentistry, Ain Shams University by the principal investigator. Clinical examination of the oral health status of their preschool children aged 3-5 years will be conducted by the principal investigator.
Study: NCT05895747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose 5-hydroxytryptophan
Description: 5-hydroxytryptophan 100mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose 5-hydroxytryptophan
Description: 5-hydroxytryptophan 200mg PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Creatine Monohydrate
Description: Creatine monohydrate 5g PO qday

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Creatine Monohydrate
Description: Creatine monohydrate 10g PO qday

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Creatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)
Study: NCT05761405

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: mannitol-enhanced aminoglycoside
Description: Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics (± mannitol) will be delivered in a single infusion that will be administered within 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxon
Description: Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.~Procedures: Consented patients will be randomized for the type of antibiotic prophylaxis according to a global randomization list (i.e. CRO, AMK, AMK1/2+MAN)).~Antibiotics will be delivered in a single infusion that will be administered within 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amikacin
Description: Preselected patients with ureteral stents in situ who are scheduled to undergo endourological ureteral stent manipulation will have routine urine cultures prior to intervention.
Study: NCT05474924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide intrapolyp injection
Description: intrapolyp injection of budesonide in cases of nasal polyps and assessment of side effects compared to systemic steroids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide nasal wash
Description: Budesonide Nasal wash in cases of nasal polyp 0.5 mg/2ml added to 250 ml normal saline using squeeze bottle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone tablets
Description: oral prednisolone tablet dosage 1 mg/kg/d tapered daily for 2 weeks.
Study: NCT05895747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Creatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)
Study: NCT06460220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe Alternatives for Teens and Youth - Parent (SAFETY-P)
Description: The parent component of SAFETY focuses on enhancing parents' skills in supporting youth safety and managing parental distress during a suicidal crisis, ideal content to adapt for web-based delivery for parents. Specifically, parent information includes psychoeducation about suicide risk and protective factors, lethal means restriction, development of a parent distress tolerance plan (i.e., Parent Safety Plan), parent self-care and sources of support, strengthening the youth/parent relationship, and focus on care linkage for the youth. The SAFETY-P asynchronous parent intervention module will include text, interactive handouts, vignettes, and short video examples. The SAFETY-P module will allow for parents to access information and skills training on their own time, with the opportunity and encouragement to ask informed questions of their child's clinician; this will provide clinicians the opportunity to utilize their check-ins with parents more effectively to address youth safety.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment As Usual (TAU)
Description: TAU will consist of treatment and case management as usual in the NCH Critical Assessment and Treatment (CATC) program. This may include individual and group therapy sessions for the youth, family therapy, medication management, and case management/discharge planning. Frequency of these services varies by availability and care linkage to ongoing outpatient care. We will track the number, type and length of all treatment and case management services provided as part of TAU in CATC to control for time spent in by parents and youth in TAU across study conditions. Additionally, the Child and Adolescent Services Assessment (CASA), a services use measure, will be utilized to capture any additional treatments and parents' involvement in those treatments.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment As Usual (TAU)
Description: TAU will consist of treatment and case management as usual in the NCH Critical Assessment and Treatment (CATC) program. This may include individual and group therapy sessions for the youth, family therapy, medication management, and case management/discharge planning. Frequency of these services varies by availability and care linkage to ongoing outpatient care. We will track the number, type and length of all treatment and case management services provided as part of TAU in CATC to control for time spent in by parents and youth in TAU across study conditions. Additionally, the Child and Adolescent Services Assessment (CASA), a services use measure, will be utilized to capture any additional treatments and parents' involvement in those treatments.
Study: NCT04788004

Intervention type: OTHER
Intervention: Online survey
Description: There are no interventions planned for this study. This is an observational study only.

Intervention type: OTHER
Intervention: Online survey
Description: There are no interventions planned for this study. This is an observational study only.

Intervention type: OTHER
Intervention: Online survey
Description: There are no interventions planned for this study. This is an observational study only.

Intervention type: OTHER
Intervention: Online survey
Description: There are no interventions planned for this study. This is an observational study only.

Intervention type: OTHER
Intervention: Online survey
Description: There are no interventions planned for this study. This is an observational study only.

Intervention type: OTHER
Intervention: Online survey
Description: There are no interventions planned for this study. This is an observational study only.

Intervention type: OTHER
Intervention: Online survey
Description: There are no interventions planned for this study. This is an observational study only.

Intervention type: OTHER
Intervention: Online survey
Description: There are no interventions planned for this study. This is an observational study only.

Intervention type: OTHER
Intervention: Online survey
Description: There are no interventions planned for this study. This is an observational study only.
Study: NCT05912894

Intervention type: PROCEDURE
Intervention: Videolaparoscopic cholecystectomy
Description: Evaluation of Rouvière's Sulcus Anatomical Variation.
Study: NCT06251466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iHealth Gluco-Smart application
Description: iHealth Gluco-Smart is an application where blood glucose measurements can be registered. This application can be coupled to a platform in the hospital, called Dharma, that enables the researchers to evaluate these blood glucose levels.
Study: NCT05596461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Setting up a new target for rTMS. In the past research, the common target of rTMS in the treatment of cognitive impairment of affective disorder was left Dorsolateral prefrontal CORTEX (DLPFC) . The left lateral DLPFC and the primary visual Cortex (V1) both play important roles in cognitive process. The regions with the strongest functional connection between V1 and DLPFC were selected as the stimulation targets.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Targeted multi-channel tDCS based on individualized simulation scale can be combined with individualized simulation modeling optimization, and based on individual MRI information, through quantitative evaluation and intelligent algorithms to achieve stimulation parameter optimization, reduce the stimulation dose to non-target target areas, and improve target brain stimulation The treatment targeting and aggregation of the area can realize personalized and precise treatment.
Study: NCT05489354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth psychoeducational intervention
Description: The mPEI program will be delivered through a mobile application (app). The app has five components which include: Breast cancer education, coping skills training, discussion forum, nurse-led consultation, and psychological support. Breast cancer education and coping skills training will be conducted by the principal investigator for 30 minutes per week for six weeks and will be delivered via text, audio and video on the mobile app. Group discussion will be moderated by the principal investigator in a text format for 30 minutes per week. Nurse-led consultation and psychological support will be provided by the oncology nurse on the research team through a 15-20-minute call in the first week, third week and fifth week.
Study: NCT04674111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporary Percutaneous Transvalvular Circulatory Support System (Vortex System)
Description: The Vortex System is intended to provide temporary circulatory support in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).
Study: NCT06024616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TARANG
Description: TARANG is aimed to empower young women to navigate newly formed relationships, improve women's awareness of sexual reproductive health, and challenge inequitable gender norms, with an aim to reduce unintended pregnancies and increase use of family planning. The TARANG intervention for newly married women will include 14 group sessions delivered by trained moderators from Vikalp. It will cover three overarching themes, including norms, empowerment, and sexual and reproductive health and wellbeing.~Four light-touch sessions for mothers-in-law and one in-person session for husbands of newly married women will be conducted. For husbands, TARANG will include one 2-hour group session within the first month of the intervention, followed by regular and moderated content delivery via videos and take-home exercises over WhatsApp groups. Vikalp will conduct door-to-door listing, and a research team from NEERMAN will recruit households into the study depending on the eligibility criteria.
Study: NCT04797273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy
Description: 12 week Internet-based cognitive behavior therapy, delivered via an online treatment platform. The treatment includes components such as exercises in conducting recuperating activities, methods to improve sleep, exposure, and behavioral activation. The treatment content is provided through written texts, images and audiofiles in the treatment platform. The participant has access to a therapist who provides support throughout the treatment via asynchronous text messages.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based structured treatment-as-usual
Description: This is a 12-week treatment, delivered via an online treatment platform. The treatment components in this treatment are designed to be similar to what is typically provided in primary care to these patients and includes information about stress and how different factors such as eating habits, physical exercise, and alcohol can contribute to stress problems. The treatment content is provided through written texts, images and audiofiles in the treatment platform. The participant has access to a therapist who provides support throughout the treatment via asynchronous text messages.